Charles L Bennett MD PhD MPP, Director, SmartState Center for Medication Safety and Efficacy at the University of South Carolina College of Pharmacy and formerly the initial AC Buehler Chairman of Medicine and Economics at the Northwestern University Feinberg School of Medicine and Kellogg School of Management and an international leader in pharmacovigilance. Supported by > $25 million in peer-reviewed grant funds from the National Institutes of Drug Abuse, the National Institutes of Health, the National Cancer Institute, the Department of Veterans Administration, and the American Cancer Society beginning in 1989, Dr. Bennett has published > 500 peer-reviewed manuscripts in medical and policy journals including first-authored papers in NEJM, JAMA, Lancet, Lancet Oncology, Lancet Haematology, the Journal of the National Cancer Institute, the Journal of Clinical Oncology, Blood, and the Annals of Internal Medicine. Born in Pittsburgh, following graduation from an inner city high school, Bennett was educated at Swarthmore College (BA ’77- Phi Beta Kappa and high honors graduate), the University of Pennsylvania School of Medicine (MD ’81), and the RAND Pardee School of Public Policy (PhD and Masters in Public Policy (1987- 1989).  His training was in internal medicine (Michael Reese Hospital (81-84)), Hematology/Oncology (University of Chicago (84-87), and post-doctoral health services research, RAND Corporation (1987- 1991).  Academic positions include Consultant Physician (UCLA), Assistant Professor (Duke (91-94), Associate Professor, Professor, and Endowed Chair Professor (Northwestern (94-2010), and Endowed Chair and Center Director (University of South Carolina (2010- current). His funded research identified epoetin-associated pure red cell aplasia (NEJM 2004), clopidogrel-associated thrombotic thrombocytopenic purpura (NEJM 2000), peginesatide-associated fatal anaphylaxis (NEJM 2014); epoetin- and darbepoetin-associated mortality among cancer patients (JAMA 2008); Paxlovid-associated COVID-19 rebound (revision under review at PLOS One), ciprofloxacin- and levofloxacin-associated long-term neuropsychiatric toxicity (Annals of Internal Medicine, under review), rituximab-associated progressive multifocal leukoencephalopathy (Blood 2007), and COVID-19 vaccine-associated hematologic toxicities (Lancet Haematology 2022).  His work has been reviewed by Anne Trontell MD, former head of FDA’s Office of Surveillance and Epidemiology (NEJM 2004- “The Prepared Mind) and Alistair JJ Wood MD PhD, Vanderbilt University (Thrombotic Thrombocytopenic Purpura and Clopidogrel—A Need for New Approaches- NEJM 2000). Bennett is responsible for 57 Black Box Warnings, eight drugs being removed from marketing, three drugs being returned to the market, and 117 package insert revisions. His work is disseminated on the Fox Television Series by Amy Holden Jones called “The Resident” (Season 3, episode 7, “Woman Down” (epoetin and darbepoetin associated mortality) and Season 3, episode 10, “The Whistleblower” (FDA’s investigation of epoetin and darbepoetin) and in a January 2023 biography (Taking on Big Pharma: Dr Charles Bennett’s Battle) from Skyhorse Publishing (a Simon and Schuster subsidiary) written by the former President of the American Association of University Professors Julius Getman JD (Law professor at Yale, Stanford, the University of Chicago, and emeritus Sheffield Professor at U of Texas) and Terri Leclerq. The audiobook is read by Stephen Lang (Colonel Quaritch, from James Cameron’s Avatar 1 and 2). The Executive Producer of a hoped for movie is All Ruddy (co-producer of the Godfather) who wrote “This book is better than the Godfather, I personally endorse the movie.”  Candidates to play Bennett include Mark Ruffalo (Spotlight), Tim Robbins (Dark Waters), Michael Keaton (Dopesick), and Stephen Lang (Avatar). Votes are being recorded in written reviews from readers on Barnes and Noble web-site (Ruffalo is the current leader to date).